LEADER 01767nam  2200469Ka 450 
001 9910696380003321
005 20080103080423.0
035   $a(CKB)5470000002377028
035   $a(OCoLC)186941514
035   $a(EXLCZ)995470000002377028
100   $a20080103d2007      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCoverage and pricing of drugs that can be covered under Part B and Part D$b[electronic resource] $efinal report /$fElizabeth Hargrave, Jack Hoadley and Jennifer Thompson ; submitted to the Medicare Payment Advisory Commission
210  1$aWashington, DC :$cMedPAC,$d[2007]
215   $a53 pages $cdigital, PDF file
225 1 $a[MedPAC contract research series] ;$v07-6
300   $aTitle from title screen (viewed Jan. 2, 2008).
300   $a"October, 2007."
320   $aIncludes bibliographical references.
517   $aCoverage and pricing of drugs that can be covered under Part B and Part D 
606   $aMedicare
606   $aDrugs$xPrices$zUnited States
606   $aPharmaceutical services insurance$zUnited States
606   $aHealth insurance claims$zUnited States
615  0$aMedicare.
615  0$aDrugs$xPrices
615  0$aPharmaceutical services insurance
615  0$aHealth insurance claims
700   $aHargrave$b Elizabeth$01390567
701   $aHoadley$b Jack$01388689
701   $aThompson$b Jennifer$01418881
712 02$aMedicare Payment Advisory Commission (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696380003321
996   $aCoverage and pricing of drugs that can be covered under Part B and Part D$93531539
997   $aUNINA